Lyell Immunopharma, Inc. (LYEL) 8-K Summary
Date of Event: October 31, 2025
Item 5.02 reports significant changes to the finance leadership structure:
- CEO Transition: Dr. Lynn Seely (President, CEO) was concurrently appointed as the Company’s interim principal financial officer.
- New Accounting Officer: Veronica Sanchez Bulis, VP, Corporate Controller since 2021, was appointed as the principal accounting officer.
...This filing documents the assumption of the interim CFO role by the current CEO alongside the formal appointment of a principal accounting officer.